CA2025695A1 - Anticorps chimeriques contre les cancers resistants aux drogues et procede de production - Google Patents

Anticorps chimeriques contre les cancers resistants aux drogues et procede de production

Info

Publication number
CA2025695A1
CA2025695A1 CA002025695A CA2025695A CA2025695A1 CA 2025695 A1 CA2025695 A1 CA 2025695A1 CA 002025695 A CA002025695 A CA 002025695A CA 2025695 A CA2025695 A CA 2025695A CA 2025695 A1 CA2025695 A1 CA 2025695A1
Authority
CA
Canada
Prior art keywords
chain
human
chimeric
chimeric antibody
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002025695A
Other languages
English (en)
Inventor
Takashi Tsuruo
Hirofumi Hamada
Yoshikazu Kurosawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JAPANASE FOUNDATION FOR CANCER RESEARCH
Fujita Health University
Original Assignee
Takashi Tsuruo
Hirofumi Hamada
Yoshikazu Kurosawa
Japanase Foundation For Cancer Research
Fujita Health University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takashi Tsuruo, Hirofumi Hamada, Yoshikazu Kurosawa, Japanase Foundation For Cancer Research, Fujita Health University filed Critical Takashi Tsuruo
Publication of CA2025695A1 publication Critical patent/CA2025695A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002025695A 1990-03-02 1990-09-19 Anticorps chimeriques contre les cancers resistants aux drogues et procede de production Abandoned CA2025695A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2-51563 1990-03-02
JP2051563A JP2564412B2 (ja) 1990-03-02 1990-03-02 薬剤耐性癌に対するキメラ抗体およびその製造

Publications (1)

Publication Number Publication Date
CA2025695A1 true CA2025695A1 (fr) 1991-09-03

Family

ID=12890444

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002025695A Abandoned CA2025695A1 (fr) 1990-03-02 1990-09-19 Anticorps chimeriques contre les cancers resistants aux drogues et procede de production

Country Status (2)

Country Link
JP (1) JP2564412B2 (fr)
CA (1) CA2025695A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
JPS6261596A (ja) * 1985-09-11 1987-03-18 Japan Found Cancer Res 薬剤耐性癌に関するモノクロ−ナル抗体およびその製造

Also Published As

Publication number Publication date
JP2564412B2 (ja) 1996-12-18
JPH03254691A (ja) 1991-11-13

Similar Documents

Publication Publication Date Title
Fell et al. Homologous recombination in hybridoma cells: heavy chain chimeric antibody produced by gene targeting.
Oren et al. TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins
EP1124568B1 (fr) Molecules de liaison polyspecifiques et leurs utilisations
AU737910B2 (en) Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
Sahagan et al. A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen.
JP4439808B2 (ja) Ｔ細胞レセプター融合体および結合体ならびにそれらの使用方法
US5644033A (en) Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
EP0369566A2 (fr) Anticorps chimériques bifonctionnels
AU728911B2 (en) Mutants of the LAG-3 proteins, products for the expression of these mutants and use
Hamada et al. Mouse-human chimeric antibody against the multidrug transporter P-glycoprotein
US5281699A (en) Treating B cell lymphoma or leukemia by targeting specific epitopes on B cell bound immunoglobulins
Maecker et al. Prevalence of antigen receptor variants in human T cell lines and tumors.
CA2128151A1 (fr) Recepteurs de l'interleukine 12 et anticorps
AU2002238537B2 (en) Hybridoma cell line G250 and its use for producing monoclonal antibodies
Seon et al. Monoclonal antibody SN2 defining a human T cell leukemia-associated cell surface glycoprotein.
EP0511308B1 (fr) Immunoglobuline chimerique pour recepteurs de cd4
AU2002238537A1 (en) Hybridoma cell line G250 and its use for producing monoclonal antibodies
CA2025695A1 (fr) Anticorps chimeriques contre les cancers resistants aux drogues et procede de production
Lugasi et al. Murine spontaneous T‐cell leukemia constitutively expressing IL‐2 receptor—a model for human T‐cell malignancies expressing IL‐2 receptor
CA2019323A1 (fr) Anticorps km10 chimeriques humain - murin specifiques contre un antigene de cellules tumorales humaines
Parsons et al. A novel CEA vaccine stimulates T cell proliferation, γIFN secretion and CEA specific CTL responses
WO2012015662A1 (fr) Récepteur de l'il-18 en tant que nouvelle cible des lymphocytes t régulateurs dans le cancer
Ariyoshi et al. Mouse‐human chimeric antibody MH171 against the multidrug transporter P‐glycoprotein
Ragnarsson et al. Multiple myeloma cells are killed by syndecan-1-directed superantigen-activated T cells
WO1994014847A1 (fr) Immunoglobulines produites par genie genetique

Legal Events

Date Code Title Description
FZDE Dead